 Deborah Hall
Concepts (288)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fragile X Syndrome | 24 | 2021 | 169 | 7.500 |
Why?
| | Tremor | 22 | 2021 | 124 | 7.260 |
Why?
| | Ataxia | 22 | 2021 | 76 | 7.010 |
Why?
| | Fragile X Mental Retardation Protein | 25 | 2021 | 101 | 6.710 |
Why?
| | Parkinsonian Disorders | 9 | 2020 | 186 | 2.770 |
Why?
| | Parkinson Disease | 16 | 2020 | 1136 | 2.620 |
Why?
| | Trinucleotide Repeat Expansion | 10 | 2021 | 40 | 2.560 |
Why?
| | Heterozygote | 9 | 2016 | 106 | 2.200 |
Why?
| | Tinnitus | 4 | 2020 | 11 | 1.910 |
Why?
| | Supranuclear Palsy, Progressive | 8 | 2020 | 44 | 1.440 |
Why?
| | Postural Balance | 5 | 2020 | 121 | 1.390 |
Why?
| | Gait Disorders, Neurologic | 3 | 2020 | 150 | 1.380 |
Why?
| | Research Design | 5 | 2020 | 230 | 1.350 |
Why?
| | Neurology | 2 | 2018 | 108 | 1.330 |
Why?
| | Humans | 72 | 2021 | 30741 | 1.310 |
Why?
| | Cerebellar Ataxia | 2 | 2021 | 7 | 1.230 |
Why?
| | Trinucleotide Repeats | 2 | 2018 | 12 | 1.200 |
Why?
| | Executive Function | 2 | 2018 | 104 | 1.140 |
Why?
| | Aged | 38 | 2020 | 10156 | 1.090 |
Why?
| | Accidental Falls | 4 | 2020 | 112 | 1.050 |
Why?
| | Female | 46 | 2021 | 18107 | 1.040 |
Why?
| | Male | 46 | 2020 | 17552 | 1.020 |
Why?
| | Middle Aged | 39 | 2021 | 11256 | 1.020 |
Why?
| | Biomedical Research | 2 | 2018 | 85 | 0.990 |
Why?
| | Cognition Disorders | 5 | 2018 | 1064 | 0.980 |
Why?
| | Exercise Therapy | 3 | 2018 | 116 | 0.970 |
Why?
| | Spinocerebellar Degenerations | 1 | 2021 | 4 | 0.900 |
Why?
| | Psychomotor Performance | 2 | 2020 | 245 | 0.850 |
Why?
| | Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.840 |
Why?
| | Nootropic Agents | 1 | 2020 | 14 | 0.830 |
Why?
| | Patient Selection | 2 | 2018 | 259 | 0.810 |
Why?
| | Auditory Perception | 2 | 2017 | 50 | 0.790 |
Why?
| | Walking | 4 | 2020 | 241 | 0.790 |
Why?
| | Phenotype | 8 | 2021 | 368 | 0.790 |
Why?
| | Attention | 1 | 2020 | 163 | 0.780 |
Why?
| | Delphi Technique | 2 | 2020 | 23 | 0.750 |
Why?
| | Hearing | 2 | 2021 | 18 | 0.750 |
Why?
| | Movement Disorders | 2 | 2016 | 140 | 0.730 |
Why?
| | Acoustics | 1 | 2017 | 17 | 0.710 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 386 | 0.700 |
Why?
| | Psychotherapy | 1 | 2017 | 42 | 0.680 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 209 | 0.660 |
Why?
| | Memory Disorders | 2 | 2016 | 180 | 0.650 |
Why?
| | Cerebral Hemorrhage | 4 | 2021 | 132 | 0.600 |
Why?
| | DNA Methylation | 1 | 2016 | 165 | 0.580 |
Why?
| | Cognition | 3 | 2020 | 1141 | 0.580 |
Why?
| | Severity of Illness Index | 11 | 2020 | 1233 | 0.570 |
Why?
| | Mutation | 3 | 2021 | 457 | 0.560 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 473 | 0.550 |
Why?
| | Adult | 18 | 2021 | 9760 | 0.530 |
Why?
| | Treatment Outcome | 10 | 2020 | 3850 | 0.520 |
Why?
| | Acoustic Stimulation | 1 | 2013 | 67 | 0.520 |
Why?
| | African Americans | 1 | 2020 | 780 | 0.500 |
Why?
| | Case-Control Studies | 9 | 2021 | 694 | 0.490 |
Why?
| | Genetic Testing | 4 | 2021 | 76 | 0.480 |
Why?
| | Alleles | 3 | 2020 | 230 | 0.470 |
Why?
| | Neuropsychological Tests | 7 | 2020 | 1278 | 0.470 |
Why?
| | Aged, 80 and over | 15 | 2020 | 5172 | 0.460 |
Why?
| | Communication Disorders | 1 | 2011 | 5 | 0.450 |
Why?
| | Activities of Daily Living | 4 | 2017 | 472 | 0.440 |
Why?
| | Deafness | 2 | 2021 | 12 | 0.430 |
Why?
| | Chromosomes, Human, X | 2 | 2009 | 9 | 0.430 |
Why?
| | Cochlear Implantation | 2 | 2021 | 18 | 0.430 |
Why?
| | Gait | 4 | 2020 | 388 | 0.420 |
Why?
| | Chromosomes, Human, Y | 1 | 2009 | 1 | 0.410 |
Why?
| | Sex Chromosome Aberrations | 1 | 2009 | 2 | 0.410 |
Why?
| | Shoulder Pain | 1 | 2010 | 57 | 0.410 |
Why?
| | Speech Perception | 2 | 2021 | 56 | 0.410 |
Why?
| | Dopamine | 1 | 2010 | 162 | 0.400 |
Why?
| | Quinolones | 1 | 2009 | 23 | 0.390 |
Why?
| | Pilot Projects | 3 | 2020 | 440 | 0.380 |
Why?
| | Dyskinesia, Drug-Induced | 1 | 2009 | 51 | 0.380 |
Why?
| | Consensus | 2 | 2020 | 96 | 0.370 |
Why?
| | Antipsychotic Agents | 1 | 2009 | 90 | 0.370 |
Why?
| | Piperazines | 1 | 2009 | 98 | 0.350 |
Why?
| | Students, Health Occupations | 1 | 2007 | 5 | 0.350 |
Why?
| | Science | 1 | 2007 | 6 | 0.350 |
Why?
| | Celiac Disease | 1 | 2007 | 10 | 0.350 |
Why?
| | Dystonia | 1 | 2007 | 55 | 0.330 |
Why?
| | Central Nervous System Agents | 1 | 2006 | 8 | 0.330 |
Why?
| | Pregnancy in Diabetics | 1 | 2006 | 4 | 0.330 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 39 | 0.330 |
Why?
| | Fetal Distress | 1 | 2006 | 2 | 0.330 |
Why?
| | Teaching | 1 | 2007 | 62 | 0.330 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2006 | 16 | 0.330 |
Why?
| | Infant, Newborn, Diseases | 1 | 2006 | 18 | 0.330 |
Why?
| | Retrospective Studies | 7 | 2018 | 3456 | 0.310 |
Why?
| | Seizures | 1 | 2006 | 86 | 0.310 |
Why?
| | Cross-Sectional Studies | 5 | 2020 | 957 | 0.310 |
Why?
| | Disability Evaluation | 5 | 2016 | 330 | 0.290 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2004 | 1 | 0.280 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 4 | 0.280 |
Why?
| | United States | 3 | 2020 | 2467 | 0.280 |
Why?
| | Chorea | 1 | 2004 | 12 | 0.280 |
Why?
| | Exercise | 3 | 2017 | 431 | 0.280 |
Why?
| | Quality of Life | 3 | 2020 | 636 | 0.270 |
Why?
| | RNA, Messenger | 3 | 2018 | 361 | 0.270 |
Why?
| | Time Factors | 5 | 2020 | 1911 | 0.260 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2021 | 119 | 0.260 |
Why?
| | Alzheimer Disease | 1 | 2014 | 1751 | 0.260 |
Why?
| | Cohort Studies | 4 | 2016 | 1959 | 0.250 |
Why?
| | Weather | 2 | 2019 | 14 | 0.240 |
Why?
| | Incidence | 3 | 2020 | 827 | 0.240 |
Why?
| | Biomechanical Phenomena | 4 | 2020 | 712 | 0.230 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2021 | 7 | 0.230 |
Why?
| | Cerebral Amyloid Angiopathy | 2 | 2019 | 94 | 0.220 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2021 | 17 | 0.220 |
Why?
| | Ovary | 1 | 2021 | 35 | 0.220 |
Why?
| | Risk Factors | 7 | 2021 | 2611 | 0.220 |
Why?
| | Martial Arts | 1 | 2020 | 5 | 0.220 |
Why?
| | Speech Disorders | 1 | 2020 | 15 | 0.220 |
Why?
| | Vision Disorders | 1 | 2020 | 26 | 0.220 |
Why?
| | Hearing Loss, Unilateral | 1 | 2020 | 1 | 0.210 |
Why?
| | Hyperglycemia | 1 | 2020 | 47 | 0.210 |
Why?
| | Hearing Aids | 1 | 2020 | 3 | 0.210 |
Why?
| | Time and Motion Studies | 1 | 2020 | 13 | 0.210 |
Why?
| | Brain | 3 | 2021 | 1574 | 0.210 |
Why?
| | Menopause | 1 | 2021 | 118 | 0.210 |
Why?
| | Hypertension | 2 | 2019 | 272 | 0.210 |
Why?
| | Prevalence | 2 | 2020 | 546 | 0.210 |
Why?
| | Blood Glucose | 1 | 2020 | 136 | 0.200 |
Why?
| | Societies, Medical | 2 | 2019 | 203 | 0.200 |
Why?
| | Chemokine CCL5 | 1 | 2019 | 22 | 0.200 |
Why?
| | Brain Ischemia | 1 | 2021 | 117 | 0.200 |
Why?
| | Th17 Cells | 1 | 2019 | 33 | 0.200 |
Why?
| | Academies and Institutes | 1 | 2018 | 12 | 0.190 |
Why?
| | Research Subjects | 1 | 2018 | 11 | 0.190 |
Why?
| | Sample Size | 1 | 2018 | 27 | 0.190 |
Why?
| | Electroencephalography | 2 | 2013 | 144 | 0.190 |
Why?
| | Health Services Accessibility | 1 | 2020 | 111 | 0.190 |
Why?
| | Dopaminergic Neurons | 1 | 2019 | 50 | 0.190 |
Why?
| | Genotype | 3 | 2016 | 447 | 0.180 |
Why?
| | Gene-Environment Interaction | 1 | 2018 | 19 | 0.180 |
Why?
| | Age of Onset | 2 | 2016 | 115 | 0.180 |
Why?
| | Substantia Nigra | 1 | 2019 | 157 | 0.180 |
Why?
| | Estrogens | 1 | 2018 | 36 | 0.180 |
Why?
| | Ibuprofen | 1 | 2017 | 12 | 0.180 |
Why?
| | Motor Activity | 2 | 2020 | 395 | 0.180 |
Why?
| | Endpoint Determination | 1 | 2017 | 31 | 0.170 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 83 | 0.170 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2017 | 7 | 0.170 |
Why?
| | Colorado | 2 | 2007 | 5 | 0.170 |
Why?
| | Prospective Studies | 5 | 2021 | 1891 | 0.170 |
Why?
| | Mosaicism | 1 | 2016 | 8 | 0.170 |
Why?
| | Siblings | 1 | 2016 | 19 | 0.170 |
Why?
| | Exercise Test | 1 | 2018 | 120 | 0.170 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 109 | 0.170 |
Why?
| | Comprehension | 1 | 2016 | 31 | 0.160 |
Why?
| | Congresses as Topic | 1 | 2016 | 35 | 0.160 |
Why?
| | Water Wells | 1 | 2016 | 1 | 0.160 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 631 | 0.160 |
Why?
| | Uric Acid | 1 | 2016 | 14 | 0.160 |
Why?
| | Environmental Exposure | 1 | 2016 | 18 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 91 | 0.160 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 228 | 0.160 |
Why?
| | Occupational Diseases | 1 | 2016 | 26 | 0.160 |
Why?
| | Child | 3 | 2013 | 1547 | 0.150 |
Why?
| | Computers | 1 | 2015 | 26 | 0.150 |
Why?
| | Early Diagnosis | 1 | 2015 | 76 | 0.150 |
Why?
| | Follow-Up Studies | 4 | 2010 | 2046 | 0.150 |
Why?
| | Reaction Time | 1 | 2015 | 120 | 0.150 |
Why?
| | Animals | 4 | 2021 | 5221 | 0.150 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 101 | 0.150 |
Why?
| | Chronic Disease | 1 | 2017 | 542 | 0.150 |
Why?
| | Range of Motion, Articular | 1 | 2018 | 697 | 0.140 |
Why?
| | Regression Analysis | 1 | 2015 | 323 | 0.140 |
Why?
| | Young Adult | 3 | 2013 | 2249 | 0.140 |
Why?
| | Hyperkinesis | 1 | 2013 | 12 | 0.140 |
Why?
| | Auditory Pathways | 1 | 2013 | 1 | 0.130 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 20 | 0.130 |
Why?
| | Audiometry, Pure-Tone | 1 | 2013 | 13 | 0.130 |
Why?
| | England | 1 | 2013 | 22 | 0.130 |
Why?
| | Psychoacoustics | 1 | 2013 | 13 | 0.130 |
Why?
| | Cerebellar Diseases | 1 | 2013 | 11 | 0.130 |
Why?
| | Adolescent | 3 | 2013 | 2627 | 0.130 |
Why?
| | Clinical Protocols | 1 | 2013 | 74 | 0.130 |
Why?
| | Neuronal Plasticity | 1 | 2013 | 50 | 0.130 |
Why?
| | Equipment Design | 1 | 2013 | 204 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 3 | 2016 | 1244 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2013 | 550 | 0.120 |
Why?
| | Sex Factors | 2 | 2011 | 535 | 0.120 |
Why?
| | Neurologic Examination | 3 | 2008 | 160 | 0.120 |
Why?
| | Social Behavior Disorders | 1 | 2011 | 6 | 0.110 |
Why?
| | Language Disorders | 1 | 2011 | 12 | 0.110 |
Why?
| | Pedigree | 2 | 2008 | 86 | 0.110 |
Why?
| | Cyclohexanols | 1 | 2010 | 18 | 0.110 |
Why?
| | Memantine | 1 | 2010 | 12 | 0.110 |
Why?
| | Point Mutation | 2 | 2008 | 38 | 0.110 |
Why?
| | Cocaine | 1 | 2010 | 45 | 0.100 |
Why?
| | Odds Ratio | 1 | 2011 | 328 | 0.100 |
Why?
| | Corpus Striatum | 1 | 2010 | 116 | 0.100 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 83 | 0.100 |
Why?
| | Atmospheric Pressure | 2 | 2019 | 12 | 0.100 |
Why?
| | Palate, Soft | 1 | 2008 | 1 | 0.090 |
Why?
| | Alexander Disease | 1 | 2008 | 1 | 0.090 |
Why?
| | Heredodegenerative Disorders, Nervous System | 1 | 2008 | 2 | 0.090 |
Why?
| | Exercise Tolerance | 1 | 2007 | 29 | 0.090 |
Why?
| | Glutens | 1 | 2007 | 1 | 0.090 |
Why?
| | Jejunum | 1 | 2007 | 14 | 0.090 |
Why?
| | Chromosome Mapping | 1 | 2007 | 61 | 0.090 |
Why?
| | Research Support as Topic | 1 | 2007 | 20 | 0.090 |
Why?
| | Universities | 1 | 2007 | 29 | 0.090 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2007 | 33 | 0.090 |
Why?
| | North America | 2 | 2018 | 43 | 0.090 |
Why?
| | Guidelines as Topic | 1 | 2007 | 78 | 0.080 |
Why?
| | Education | 1 | 2007 | 42 | 0.080 |
Why?
| | Child, Preschool | 1 | 2009 | 803 | 0.080 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2007 | 38 | 0.080 |
Why?
| | Cholinesterase Inhibitors | 1 | 2006 | 20 | 0.080 |
Why?
| | Carbidopa | 1 | 2006 | 45 | 0.080 |
Why?
| | Benzodiazepines | 1 | 2006 | 59 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2006 | 45 | 0.080 |
Why?
| | Dopamine Agonists | 1 | 2006 | 46 | 0.080 |
Why?
| | Age Factors | 2 | 2021 | 941 | 0.080 |
Why?
| | Levodopa | 1 | 2006 | 138 | 0.080 |
Why?
| | Biopsy | 1 | 2007 | 286 | 0.080 |
Why?
| | Serotonin Uptake Inhibitors | 1 | 2006 | 90 | 0.080 |
Why?
| | Internet | 1 | 2007 | 98 | 0.080 |
Why?
| | Population Surveillance | 1 | 2006 | 129 | 0.080 |
Why?
| | Anxiety Disorders | 1 | 2006 | 175 | 0.070 |
Why?
| | Pregnancy | 1 | 2006 | 452 | 0.070 |
Why?
| | Registries | 1 | 2006 | 203 | 0.070 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 233 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2020 | 1432 | 0.070 |
Why?
| | DNA Repeat Expansion | 1 | 2004 | 6 | 0.070 |
Why?
| | RNA-Binding Proteins | 1 | 2004 | 26 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2006 | 751 | 0.070 |
Why?
| | Disease Progression | 3 | 2016 | 851 | 0.070 |
Why?
| | Uterine Diseases | 1 | 2002 | 2 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2004 | 172 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2019 | 831 | 0.060 |
Why?
| | Endometriosis | 1 | 2002 | 19 | 0.060 |
Why?
| | Task Performance and Analysis | 2 | 2013 | 58 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2004 | 469 | 0.060 |
Why?
| | Fertility | 1 | 2021 | 16 | 0.060 |
Why?
| | Animals, Genetically Modified | 1 | 2021 | 18 | 0.060 |
Why?
| | Drosophila melanogaster | 1 | 2021 | 21 | 0.060 |
Why?
| | Physical Therapy Modalities | 2 | 2012 | 71 | 0.060 |
Why?
| | Proteome | 1 | 2021 | 23 | 0.060 |
Why?
| | Cross-Over Studies | 1 | 2021 | 81 | 0.060 |
Why?
| | Noise | 1 | 2020 | 32 | 0.050 |
Why?
| | Genome-Wide Association Study | 1 | 2021 | 308 | 0.050 |
Why?
| | Cochlear Implants | 1 | 2020 | 26 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2020 | 283 | 0.050 |
Why?
| | Nerve Degeneration | 1 | 2019 | 57 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2004 | 876 | 0.050 |
Why?
| | Temperature | 1 | 2018 | 84 | 0.050 |
Why?
| | Risk Assessment | 1 | 2021 | 804 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 538 | 0.040 |
Why?
| | Hospitalization | 1 | 2020 | 344 | 0.040 |
Why?
| | Comorbidity | 1 | 2019 | 562 | 0.040 |
Why?
| | Prognosis | 1 | 2020 | 1045 | 0.040 |
Why?
| | Eye Movements | 1 | 2016 | 25 | 0.040 |
Why?
| | Self Report | 1 | 2018 | 217 | 0.040 |
Why?
| | Accelerometry | 1 | 2017 | 88 | 0.040 |
Why?
| | Logistic Models | 1 | 2018 | 479 | 0.040 |
Why?
| | Protective Factors | 1 | 2016 | 18 | 0.040 |
Why?
| | Posture | 1 | 2016 | 88 | 0.040 |
Why?
| | Occupational Exposure | 1 | 2016 | 27 | 0.040 |
Why?
| | Neuroimaging | 1 | 2016 | 122 | 0.040 |
Why?
| | Chicago | 1 | 2018 | 945 | 0.040 |
Why?
| | Mice | 1 | 2019 | 1843 | 0.030 |
Why?
| | Video Recording | 1 | 2014 | 49 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2013 | 132 | 0.030 |
Why?
| | Movement | 1 | 2013 | 167 | 0.030 |
Why?
| | Mental Health | 1 | 2013 | 114 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2013 | 362 | 0.030 |
Why?
| | Health Status | 1 | 2013 | 252 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 162 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 181 | 0.030 |
Why?
| | Linear Models | 1 | 2011 | 277 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 266 | 0.030 |
Why?
| | Pons | 1 | 2008 | 4 | 0.020 |
Why?
| | Mental Processes | 1 | 2008 | 17 | 0.020 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2008 | 37 | 0.020 |
Why?
| | Intelligence | 1 | 2008 | 28 | 0.020 |
Why?
| | Family Health | 1 | 2007 | 41 | 0.020 |
Why?
| | Verbal Learning | 1 | 2008 | 43 | 0.020 |
Why?
| | Atrophy | 1 | 2008 | 107 | 0.020 |
Why?
| | Memory, Short-Term | 1 | 2008 | 98 | 0.020 |
Why?
| | Gene Silencing | 1 | 2007 | 26 | 0.020 |
Why?
| | Patient Compliance | 1 | 2007 | 201 | 0.020 |
Why?
| | Mass Screening | 1 | 2007 | 199 | 0.020 |
Why?
| | California | 1 | 2004 | 34 | 0.020 |
Why?
| | Endometrium | 1 | 2002 | 7 | 0.020 |
Why?
| | Leiomyoma | 1 | 2002 | 11 | 0.020 |
Why?
| | Uterine Neoplasms | 1 | 2002 | 13 | 0.020 |
Why?
| | Ultrasonography | 1 | 2002 | 204 | 0.010 |
Why?
|
|
Hall's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|